netFormulary Berkshire West NHS NHS
Royal Berkshire Foundation Trust
Berkshire Healthcare NHS Foundation Trust
Newbury and District CCG
North and West Reading CCG
South Reading CCG
Wokingham CCG
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
Notes:
This formulary is used by multiple organisations. There may be some instances where an item is on the formulary for one organisation but not the others. To help distinguish between each organisation, text will be colour coded, i.e. information relating to the Royal Berkshire NHS Foundation Trust will be in blue and Berkshire Healthcare NHS Foundation Trust will be in purple. Please ensure you read all information detailed under a drug.   
 Useful Links
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
08.01 Cytotoxic drugs (1,0)
Side-effects of cytotoxic drugs (0,1)
Drugs for cytotoxic-induced side-effects (2,5)
08.01.01 Alkylating drugs (9,3)
08.01.02 Anthracyclines and other cytotoxic antibiotics (10,3)
08.01.03 Antimetabolites (13,4)
08.01.04 Vinca alkaloids and etoposide (5,5)
08.01.05 Other antineoplastic drugs (20,0)
Amsacrine (1,0)
Arsenic trioxide (0,1)
Bevacizumab (1,0)
Bexarotene (0,1)
Bortezomib (1,0)
Cetuximab (1,0)
Crisantaspase (1,0)
Dacarbazine and Temozolomide (2,0)
Erlotinib (1,0)
Hydroxycarbamide (1,0)
Imatinab (0,0)
Ipilimumab (1,0)
Mitotane (0,1)
Panitumumab (1,0)
Pentostatin (0,1)
Platinum compounds (3,2)
Porfimer sodium and temoporfin (0,2)
Procarbazine (1,0)
Protein kinase inhibitors (18,3)
Taxanes (3,2)
Topoisomerase I inhibitors (3,0)
Trabectedin (1,0)
Trastuzumab (2,0)
Tretinoin (0,1)
08.02 Drugs affecting the immune response (0,0)
Immunosuppressant therapy (0,0)
08.02.01 Antiproliferative immunosuppressants (2,2)
08.02.02 Corticosteroids and other immunosuppressants (8,4)
08.02.03 Rituximab and alemtuzumab (2,0)
08.02.04 Other immunomodulating drugs (7,1)
Interferon Alfa (5,1)
Interferon beta (1,5)
Aldesleukin (1,2)
Glatiramer acetate (1,0)
Lenalidomide, pomalidomide, and thalidomide (1,0)
Natalizumab (1,0)
08.03 Sex hormones and hormone antagonists in malignant disease (0,0)
08.03.01 Oestrogens (2,0)
08.03.02 Progestogens (4,0)
08.03.03 Androgens (0,0)
08.03.04 Hormone antagonists (0,0)
08.03.04.01 Breast cancer (5,3)
08.03.04.02 Prostate cancer and gonadorelin analogues (0,0)
Gonadorelin analogues (1,1)
Anti-androgens (6,2)
08.03.04.03 Somatostatin analogues (1,3)
netFormulary